Humanized, anti-n2 antibodies

A humanized, anti-N2 antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein:

• i. the VH region comprises three complementarity determining regions (CDRs) VH CDR1, VH CDR2 and VH CDR3 wherein the VH CDR1 comprises SEQ ID NO:
• 3, VH CDR2 comprises SEQ ID NO:
• 4 and VH CDR3 comprises SEQ ID NO:
• 5;
• ii. the VH region comprises four framework regions (FWR) VH FWR1, VH FWR2, VH FWR3 and VH FWR4 wherein:
• a. the VH FWR1 comprises SEQ ID NO:
• 15, SEQ ID NO:
• 19 or SEQ ID NO:
• 23;
• b. The VH FWR2 comprises SEQ ID NO:
• 16, SEQ ID NO:
• 20, SEQ ID NO:24 or SEQ ID NO:
• 50;
• c. VH FWR3 comprises SEQ ID NO:
• 17, SEQ ID NO:
• 21, SEQ ID NO:
• 25, SEQ ID NO:
• 43, SEQ ID NO:
• 44, SEQ ID NO:
• 45, SEQ ID NO:
• 51 or SEQ ID NO:
• 52;
• and
• d. VH FWR4 comprises SEQ ID NO:
• 18, SEQ ID NO:
• 22, or SEQ ID NO:
• 26;
• iii. the VL region comprises three complementarity determining regions (CDRs) VL CDR1, VL CDR2 and VL CDR3 wherein the VL CDR1 comprises SEQ ID NO:
• 6, VH CDR2 comprises SEQ ID NO:
• 7 and VH CDR3 comprises SEQ ID NO:
• 8;
• iv. the VL region comprises four framework regions (FWR) VL FWR1, VL FWR2, VL FWR3 and VL FWR4 wherein:
• a. the VL FWR1 comprises SEQ ID NO:
• 27, SEQ ID NO:
• 31, or SEQ ID NO:
• 35;
• b. VL FWR2 comprises SEQ ID NO:
• 28, SEQ ID NO:
• 32, or SEQ ID NO:
• 36;
• c. VL FWR3 comprises SEQ ID NO:
• 29, SEQ ID NO:
• 33, or SEQ ID NO:
• 37;
• and
• d. VL FWR4 comprises SEQ ID NO:
• 30, SEQ ID NO:
• 34, or SEQ ID NO:
• 38.

A humanized, anti-N2 antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region comprising a sequence selected from the group consisting of SEQ ID NO:

• 9, SEQ ID NO:
• 10, SEQ ID NO:
• 11 and SEQ ID NO:
• 49.

A nucleotide sequence encoding a VH region, wherein the VH region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:

• 9, SEQ ID NO:
• 10, SEQ ID NO:
• 11 and SEQ ID NO:
• 49.